Huadong Medicine Company (HMC) has completed an acquisition of Sinclair Pharma for $222m.

Sinclair Pharma will operate as a stand-alone entity following the acquisition.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The deal will enable Sinclair to expand its product pipeline for minimally invasive treatments and build partnerships with aesthetic physicians and organisations in the US.

Based in China, HMC is a manufacturer and distributor of pharmaceutical and medical products, while Sinclair Pharma is a UK-based speciality pharmaceutical company focused on dermatology.

Direct Biologics has completed an acquisition of Paisley Laboratories.

The acquisition will enhance Paisley Laboratories to develop innovative and revolutionary products based on human mesenchymal stem cells.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
“Takeda Pharmaceutical has received approval from the European Commission (EC) for an acquisition of Shire for $62bn.”

Direct Biologics is a manufacturer of regenerative medical products, while Paisley Laboratories is engaged in regenerative and restorative skincare product development.

Both companies involved in the acquisition are based in the US.

Cambrex Corporation has entered a definitive agreement to acquire Avista Pharma Solutions for approximately $252m.

The payment will be completed in a combination of cash and borrowings under Cambrex’s existing revolving credit facility.

Expected to be closed by the end of 2018, the transaction will enable Cambrex to enter the small molecule development and testing services market.

Based in the US, Cambrex is a life sciences company, while Avista Pharma is a drug development company based in the UK.

Takeda Pharmaceutical has received approval from the European Commission (EC) for an acquisition of Shire for $62bn.

The approved was granted under the condition that both companies should divest inflammatory bowel disease treatments Entyvio and SHP647.

Based in Japan, Takeda is a pharmaceutical company, while Shire is a biotechnology company based in the US.